Q4 2021

Filed Mar 31, 2022 · 10-K · 90 days after period end · 0001477932-22-001817

Q4 2021 · 10-K

derived · Computed from the longer spans the company filed.

Revenue

$13.61K

derived−38.7% vs Q4 2020

Net Income

-$1.20M

derivedN/M vs Q4 2020

EPS, diluted—

Same quarter

Metric	Q4 2021derived from reported figures	Q4 2020derived from reported figures	Q4 2019derived from reported figures	Q4 2018derived from reported figures
Revenue	$13.61K	$22.22K	$62.45K	$51.67K
Net Income	-$1.20M	-$904.67K	-$1.20M	-$2.47M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR